Key Highlights
- Loss per share of USD 0.67 matched the USD 0.67 loss estimate.
- Net loss of USD 29.66 million, against USD 23.58 million a year earlier.
- Research and development expenses were USD 25.49 million, against USD 22.09 million.
- Cash and marketable securities totaled USD 386.6 million on September 30.
Avalyn Pharma (NASDAQ:AVLN) lost USD 0.67 per share in the third quarter of 2026, exactly the loss the market had expected. The net loss was USD 29.66 million, against USD 23.58 million in the third quarter of 2025, and the loss from operations was USD 33.09 million, against USD 25.32 million. Other income was USD 3.44 million, against USD 1.74 million.
Spending by Line
Research and development expenses were USD 25.49 million, against USD 22.09 million, and general and administrative expenses were USD 7.60 million, against USD 3.23 million. Total operating expenses were USD 33.09 million, against USD 25.32 million.
Share-based compensation in total was USD 3.10 million, against USD 725 thousand. Of that, USD 1.89 million sat in general and administrative expenses and USD 1.21 million in Research and Development expenses.
Nine Months to September 30
The net loss for the nine months ended September 30, 2026 was USD 85.46 million, against USD 61.28 million. Total operating expenses were USD 92.29 million, against USD 65.82 million, with research and development at USD 73.11 million, against USD 55.29 million, and general and administrative expenses at USD 19.18 million, against USD 10.53 million. Other income was USD 6.83 million, against USD 4.54 million, and share-based compensation was USD 7.08 million, against USD 2.40 million.
Runway, Lead Candidate and IPO
At September 30, 2026, the company held USD 386.6 million of cash, cash equivalents and marketable securities. On its current operating plans, it believes this is enough for operating expenses and capital expenditures into 2029.
The lead product candidate, AP01 inhaled pirfenidone, is an optimized inhaled formulation of pirfenidone now being tested in MIST, a global Phase 2b trial in patients with progressive pulmonary fibrosis. In April 2017, the company signed a license agreement with PARI Pharma. It agreed to make payments on certain developmental and regulatory milestones for its drug product, among them the start of Phase 2 and Phase 3 trials, acceptance for filing by the FDA or the European Medicines Agency, and approval by either agency.
In its initial public offering, the company sold 19,166,667 shares of common stock at USD 18.00 per share, including 2,500,000 shares the underwriters bought on fully exercising their option, for aggregate net proceeds of about USD 316.6 million. Just before the offering closed, the outstanding redeemable convertible preferred stock converted automatically into 23,918,194 shares of common stock, leaving none outstanding.
The Quarter in Brief
Avalyn Pharma reported a loss of USD 0.67 per share and a net loss of USD 29.66 million. Research and development expenses were USD 25.49 million, and cash, cash equivalents and marketable securities were USD 386.6 million.






Please wait processing your request...